Hypertension and nephrology

[Health Protective Screening Program of Hungary 2010-2020. Metabolic syndrome - Results in 2010-2012]

KÉKES Ede, BARNA István, DAIKI Tenno, DANKOVICS Gergely, KISS István

JULY 20, 2013

Hypertension and nephrology - 2013;17(02)

[1 597 163 health assessments were performed on 65267 persons as a part of screening program. 132 964 participants were participated in our lifestyle advice program. The number of questionnaire responses for health statue were 3 717 480 during three years. This publication presents the results of metabolic disorders explored by screening. The metabolic syndrome was characterized by visceral obesity, abnormal glucose level and elevated blood pressure. Reasonable suspicion of metabolic syndrome was occured in 33-38% of subjects. Where the positive criteria was present, there were higher values of investigated parameters (waist, glucose, cholesterol, systolic blood pressure, uric acide level) compared with those of negative criteria.]

COMMENTS

0 comments

Further articles in this publication

Hypertension and nephrology

[What you need to know about the influence of abnormal lipid profiles. - New experiences]

CSÁSZÁR Albert

[Statins represent the most important drug among antilipidemic therapy modalities playing dominant roles against atherosclerotic burden. Statin’s outstanding importance is due partly to cholesterol lowering capacity, however their anti-inflammatoric, antiproliferative, antioxidant and vasodilatative efficacies as a pleiotropic potential indicates much more impact on prompt retardation of atherosclerotic progression. The results concerning statin pleiotropic influence are reviewed which are in association with their new indication in ACS management. The second part of this review delineates suspected side effects of statin use. Only one concern brings safety information: it is a fact that patients being treated with statins may have a small increased risk of increased blood sugar levels and of being diagnosed with type 2 diabetes mellitus, but the cardiovascular and mortality benefits of statin therapy exceed the diabetes hazard.]

Hypertension and nephrology

[Report on the 50th Jubilee Congress of the European Renal Association – European Dialysis and Transplant Association]

BÁNKI N. Fanni

Hypertension and nephrology

[Hypertension and diabetes mellitus]

SZEGEDI János, KISS István

[Hypertension and diabetes mellitus are endemics which affect large crowds; they play an important role in the morbidity and mortality of the population. Both diseases are cardiovascular risk factors, their co-occurrence increases the coronary risk. According to forecasts, there will be 60% increase in the number of hypertensive patients by 2025; it will affect 29% of the world’s adult population, 1.56 billion people. The number of patients with diabetes increases in all countries; 552 million diabetic patients should be expected by 2030. The simultaneous occurrence of both diseases may be a coincidence, but there is also causal relationship between the two diseases (diabetic nephropathy, metabolic syndrome). The two diseases often occur in endocrine diseases, and in connection with medicinal therapy (steroids, etc.). The simultaneous occurrence of these two diseases determines the therapeutic strategy. During the prevention and treatment of both diseases, the change in lifestyle has an important role (obesity, salt intake, physical activity).]

Hypertension and nephrology

[Practical aspects of therapy by erythropoiesis stimulating agents in renal anaemia]

DEÁK György, HERSZÉNYI Eszter, AMBRUS Csaba, KISS István

[Prevalence of renal anaemia due to insufficient production of erythropoietin increases progressively in the course of renal function deterioration. Renal anaemia is treated by erythropoesis stimulating agents (ESA). Outcomes of randomized clinical trials have taught us to avoid the strategy of normalization of hemoglobin (HGB) levels by ESA therapy as it may increase the risk of cardiovascular events and mortality. The Kidney Disease: Improving Global Outcomes (KDIGO) Clinical Practice Guideline for Anaemia published in 2012 recommends to start ESA therapy in the 90-100 g/l HGB range and suggests to keep HGB concentrations below 115 g/l. It is an inappropriate strategy to aim at normalizing hemoglobin (HGB) levels by ESA therapy because it may lead to progressive escalation of ESA doses even in the presence of diminished ESA responsiveness. High ESA doses and diseases causing ESA hyporesponsiveness eg. infections, chronic inflammation, malnutrition, insufficient dose of dialysis, severe hyperparathyroidism, iron deficiency are related to increased risk of mortality. KDIGO Clinical Practice Guideline for Anaemia emphasizes the importance of assessing and treating causes of ESA hyporesponsiveness, limits ESA dose escalation and recommends gradually changing ESA doses to avoid high amplitude HGB oscillation.]

Hypertension and nephrology

[Managing hypertension using a fixed combination of an angiotensin converting enzyme inhibitor and a calcium channel blocker]

E. Chazova, G. Ratova, V. Nedogoda, M. Lopatin, B. Perepech, V. Tsoma

[The objective of the study was to compare the efficacy of a low-dose combination of an angiotensin-converting enzyme (lisinopril 10 mg) and a dihydropyridine calcium channel blocker (amlodipine 5 mg) (Ekvator, Gedeon Richter) (Group 1) and enalapril with or without hydrochlorothiazide (Group 2) in hypertension. Materials and methods: The study included 93 patients with hypertension (36% of men and 64% of women). The mean age was 52.6±12 years and the mean duration of hypertension was 7.5±6.1 years. The initial office blood pressure (BP) was 149.2±13.8/91.4±81 mmHg. Patients were randomized into two groups (Group 1, n=51 and Group 2, n=36). Results: The fixed-dose combination of amlodipine/lisinopril offered the potential to reduce the office BP by -28.9±11.3/-16.0±8.7 mmHg; p<0.0001. In Group 2 the office BP dropped by -22.9±17.9/-11.5±10.7 mmHg; p<0.0001. Patients in Group 1 achieved goal blood pressure more frequently than patients in Group 2 (94.1% versus 72.2% patients respectively; p=0.008). There were no significant changes in the heart rate in either group. The reduction of microalbuminuria (the reduction in urinary albumin excretion (UAE)) by -13.8±24.4 mg/24h (p<0.001) was observed only in patients from Group 1. The quality of life of patients from Group 2 improved. However, the quality of life improvements were more significant in Group 1 than in Group 2 (p=0.002). Conclusion: The fixed-dose combination of amlodipine/lisinopril offers the potential to achieve a target blood pressure in 94% of patients with hypertension, produces a nephroprotective effect and improves patients’ quality of life.]

All articles in the issue

Related contents

Lege Artis Medicinae

[THE METABOLIC SYNDROME CLINICAL APPEARANCE, DIAGNOSIS, PATHOMECHANISM]

KÉKES Ede, CZURIGA István

[The metabolic syndrome has gone by several names over the past two decades. The diagnostic criteria were proposed by the ATP III of NCEP in 2001 and were accepted by European Society of Cardiology and European Society of Hypertension in 2003. The criteria (abnormal waist rate, HDLcholesterol, triglyceride, blood pressure and fasting glucose) are listed and the presence of any three of these factors is considered sufficient for diagnosis. The prevalence of syndrome affects about a quarter of the Hungarian population with hypertension. The metabolic syndrome is associated with premature cardiovascular morbidity and mortality including an excess of sudden deaths. According to the recent literature data the main component of the syndrome, the obesity, especially with abdominal fat distribution is associated with hypertension, hyperinsulinemia and insulin resistance with related abnormalities of carbohydrate and lipid metabolism. The low HDL cholesterol, high triglyceride level and the small, dense LDL cholesterol particles are the parts of lipid component of syndrome. A variety of environmental (obesity, smoking, physical inactivity) and genetic factors (genetic mutations of lipoprotein lipase, hepatic lipase, CETP and PPA receptors) and the impaired FFA metabolism have all been related to lipid abnormalities. Sympathetic hyperfunction participates in the pathogenesis and complications of metabolic syndrome. Possible factors augmenting sympathetic activation include alterations of insulin, leptin, FFA, cytokines, sleep apnoe. Other important factors as the endocrin concept, the hypothalamus-hypophysis- adrenal axis, endothelial dysfunction are discussed. The impaired muscle insulin stimulated glycogen synthesis (FFA induced GLUT-4 inhibition) is the major cellular factor of insulin resistance. There is a continuous process from the insulin resistance state (with hyperinsulinemia) into the 2T diabetes mellitus (with hypoinsulinemia).]

Lege Artis Medicinae

[NON-PHARMACOLOGIC TREATMENT OF TYPE 2 DIABETES AND METABOLIC SYNDROME]

[Type 2 diabetes mellitus and metabolic syndrome are important risk factors of cardiovascular morbidity and mortality. Both diseases present with a similar set of metabolic disturbances including hyperglycaemia, hyperlipidaemia, hypertension and obesity. Therefore, their nonpharmacological treatment is based on similar principles. Medical nutritional therapy aims to promote moderate weight loss through decreased energy intake, and to correct metabolic disturbances by ensuring appropriate composition of micro- and macronutrients. In a healthy diet, carbohydrates and cis-fatty acids make up approximately 60 to 70% of total energy intake. It is important to reduce the intake of saturated fatty acids and trans-fatty acids. The consumption of foods with low glycaemic index may be beneficial for diabetic patients. The increase of physical activity (both aerob and resistance exercise) is useful in maintaining weight loss, and it also improves blood lipid levels and blood pressure. Abandonment of smoking results in significant cardiovascular risk reduction. Lifestyle changes should include all of the above factors in order to achieve most reduction in morbidity and mortality associated with type 2 diabetes mellitus and the metabolic syndrome.]

Clinical Oncology

[Fatigue - symptom or side effect]

TOKODI Zsófia

[Cancer-related fatigue (CRF) is common in most cancer patient, which has a high impact on the quality of their life. It affects not only the patient itself, but also their families and relationships. It is the most underreported, overlooked and undertreated symptom. The screening and adequate treatment of CFR is getting more attention nowadays and it became the subject of guidelines of several international expert groups like the ASCO) and the NCCN. In this review we would like to summarize the contributory factors of CRF, the screening methods, the clinical assessment and the interventions of patients with cancer related fatigue. We try to give guidance to distinguish fatigue as a symptom of disease progression or as a side effect that we can treat. But lastly the most important question becomes that why CRF is so underreported.]

Lege Artis Medicinae

[Reducing lung cancer mortality through prevention]

KOVÁCS GÁBOR, OSTOROS Gyula, PATAKI Géza

[Effective therapy for lung cancer is yet unknown and the role of prevention has continuously increased. In practice, primary prevention of lung cancer means the reduction of smoking either by cessation or by patient education. Screening for lung cancer, considered as a secondary prevention measure, has long been debated. The previously negative attitude for screening has slowly changed in the past years. New studies have been organised recently to make screening more effective. In high risk groups, helical CT-scans with low dose X-ray exposure are preferred and the effectivity of sputum citology completed with immunocytochemical tests is under investigation. Determining the risk group, we focus on age, smoking history, airway obstruction and certain tumour markers. With the help of traditional chest X-rays approximately one third of new cases of lung cancer are discovered in Hungary. Our reasonable target is to identify 60-70% of the new NSCLC cases by risk group screening (age>40 years, smoking>20 P.Y., decrease of FEV1>15%, family lung cancer history and previous asbestos exposure) and by organising population screening more effectively.]

Image challenge

What do you see on the feet of the diabetic patient?